<DOC>
	<DOCNO>NCT00391898</DOCNO>
	<brief_summary>The study evaluate efficacy levodopa/carbidopa/entacapone v levodopa/carbidopa patient Parkinson 's disease early wearing-off levodopa</brief_summary>
	<brief_title>Efficacy Levodopa/Carbidopa/Entacapone v Levodopa/Carbidopa Parkinson 's Disease Patients With Early Wearing-off</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>1 . Male female patient age ≥ 30 ≤ 80 year old . 2 . A clinical diagnosis idiopathic Parkinson 's disease . 3 . Taking stable dose levodopa/carbidopa ( ≥ 300 ≤ 600mg ) period least 1 month prior study entry . 4 . Must use follow levodopa/carbidopa standard formulation levodopa/carbidopa 100/25mg dose intake day . 1 full tablet , and/or 1½ tablet The patient also use , period least 1 month prior study entry , 1 tablet control release formulation levodopa/carbidopa 100/25 mg ( market Spain Sinemet Plus retard ) 1 tablet control release formulation levodopa/carbidopa 200/50 mg ( market Spain Sinemet retard ) intake , different dos . 5 . Must early endofdose wearingoff define &gt; = 2 &lt; =7 positive response QUICK questionnaire . 6 . Must minimum UPDRS part II ( ADL ) score 9 . 7 . Patients without dyskinesia mild dyskinesia . 8 . Female patient must either postmenopausal use one acceptable method contraception . 9 . Must capable satisfying requirement protocol must willing able give inform consent accord legal requirement . 1 . Previous current use entacapone . 2 . History , sign , symptom suggest diagnosis secondary atypical parkinsonism . 3 . Unstable Parkinson 's disease patient . 4 . Patients experience severe dyskinesia . 5 . The following levodopa/carbidopa dos strength permit : Patients take ½ tablet standard formulation levodopa/carbidopa 100/25 Patients take standard formulation levodopa/carbidopa 100/10 250/25 Patients take few 3 6 daily intake standard formulation levodopa/carbidopa 100/25 ( few 300mg 600mg levodopa ) 6 . Patients hallucination psychiatric disease relate levodopa dopamine agonist intake . Patients major depression . 7 . Female patient pregnant , try become pregnant nursing ( lactate ) infant . 8 . Concomitant treatment MAOinhibitors ( except selegiline 10mg/day ) , rotigotine neuroleptic , within 60 day prior screen visit . 9 . Patients previous history Neuroleptic Malignant Syndrome ( NMS ) and/or nontraumatic rhabdomyolysis . 10 . Participated another trial investigational drug/device within last 30 day prior study entry . 11 . Patients history poor compliance Investigator 's judgment unlikely comply medical regimen study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Parkinson 's disease , adult , levodopa/carbidopa/entacapone , wearing-off , activity daily live</keyword>
</DOC>